Becton, Dickinson and Company (BD) reported a senior leadership transition involving Michael D. Garrison, Executive Vice President and President of the company’s Medical Essentials and BioPharma Systems segments. On July 19, 2026, Garrison informed BD that he intends to retire. The company said he will remain in his current role through the end of BD’s fiscal year to help ensure a smooth transition. BD has begun a comprehensive search for the next President of the Medical Essentials segment. As part of the transition, BD also announced an operating-model change for its BioPharma Systems segment. Going forward, that segment will report directly to Thomas E. Polen, BD’s Chairman, Chief Executive Officer and President. The company described the move as intended to streamline its operating structure. The filing was made under Item 5.02, which covers departures of directors or certain officers and related executive changes. BD also disclosed under Item 7.01 that it issued a press release on July 22, 2026, addressing the leadership change and organizational realignment. That press release was furnished as Exhibit 99.1 and, as is typical for Regulation FD disclosures, was not deemed “filed” for liability purposes under the Exchange Act. The report does not describe any securities transactions, equity awards, option exercises, share sales, prices, transaction codes, or changes in beneficial ownership. Its significance is the announcement of an upcoming executive retirement and a reporting-line change affecting two BD business segments.